- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMASIMPLE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 6,200 | -1,59 % | Innocan Pharma gibt Finanzergebnisse für 3. Quartal 2025 bekannt - mit Umsätzen von 21,6 Mio. USD | Herzliya, Israel und Calgary, Alberta - 27. November 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTC: INNPF) (das
"Unternehmen" oder "Innocan"), ein pharmazeutisches... ► Artikel lesen | |
| SYNBIOTIC | 1,612 | -3,12 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC verstärkt Präsenz auf internationalen Events und verfolgt Fortschritte in der Cannabisforschung | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Strategische Unternehmensentscheidung
SYNBIOTIC verstärkt Präsenz auf internationalen Events und verfolgt Fortschritte in der Cannabisforschung... ► Artikel lesen | |
| BIONANO GENOMICS | 1,680 | 0,00 % | Bionano Genomics: Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. "Over the last year, we have taken... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 127,20 | -0,74 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy | Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA a2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergistic... ► Artikel lesen | |
| JAGUAR HEALTH | 1,080 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study | Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved CanaleviaA novel non-antibiotic approach to diarrhea treatment is important because there... ► Artikel lesen | |
| TRULIEVE CANNABIS | 5,150 | -1,34 % | CSE Bulletin: Redemption - Trulieve Cannabis Corp. 6OCT2026 Notes (TRUL.NT.U) | Toronto, Ontario--(Newsfile Corp. - Le 3 décembre/December 2025) - Trulieve Cannabis Corp. ("Trulieve"), has announced it has issued a notice of redemption for all of its outstanding 8.0% senior... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 243,00 | +1,00 % | West Pharmaceutical: Morgan Stanley startet Coverage mit 'Equalweight'-Einstufung | ||
| KALA BIO | 0,778 | 0,00 % | Kala Pharmaceuticals: Aktie gibt nach Kapitalerhöhung über 10 Millionen Dollar nach | ||
| SHIONOGI | 14,300 | -3,38 % | Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance | ||
| THERIVA BIOLOGICS | 0,226 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results | - Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO)... ► Artikel lesen | |
| CHARLOTTES WEB | 0,068 | -11,76 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Q3 2025 Results | Healthcare Focus, Product Innovation, and Cost Improvements
LOUISVILLE, Colo., Nov. 12, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings,... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,458 | +0,88 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 03.07.2025 | The following instruments on XETRA do have their last trading day on 03.07.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 03.07.2025ISIN NameAU3CB0222354 FMO-N.FIN.-M.O. 2025... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,000 | -0,99 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE, a Preservative-Free IV Ketamine | FDA has determined that NRx's Abbreviated New Drug Application (ANDA) is "substantially complete" and received for review. Assigned GDUFA goal date is July 29, 2026.NRx has applied to FDA for use... ► Artikel lesen | |
| LUYE PHARMA | 0,332 | +1,22 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR THE GROUP'S NEW DRUG LY03017 FOR CLINICAL TRIALS IN THE U.S. | ||
| THERAPEUTICSMD | 1,420 | 0,00 % | TherapeuticsMD, Inc. - 10-Q, Quarterly Report |
Das Unternehmen PHARMASIMPLE SA kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMASIMPLE SA finden Sie auf Wallstreet Online.